Loading
TBI-1501 is an experimental CAR-T cell therapy from Takara Bio in phase 2 trials for acute lymphoblastic leukaemia, aimed at CD19.
TBI-1501 is a CAR-T cell therapy developed by Takara Bio. Its target is CD19. ClinicalTrials.gov describes the intervention as: Phase-I portion: Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\^5 cells/kg, cohort 1: 1×10\^6 cells/kg, cohort 2: 3×10\^6 cells/kg). Phase-II portion: Recommended dose of. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in acute lymphoblastic leukaemia. The largest, NCT03155191, plans to enrol 21 participants with primary completion expected 2035-03-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
CAR-T cell therapy directed at CD19, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to CD19.
1.TBI-1501 slips into a pocket on CD19.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TBI-1501" OR ABSTRACT:"TBI-1501") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TBI-1501, not a curated reading list.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Takara Bio and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.